Compounded tirzepatide recall: check your lot

October 21, 2026By the Peptide Science Desk Editorial TeamFact-checked against FDA and official sources · Oct 21, 2026Not yet reviewed by a licensed clinician. How we check facts

In short: a North Carolina pharmacy recalled 22 vials of pharmacy-made tirzepatide. FDA lists lots AP-202622 to AP-202644 (not AP-202626). If you have one, stop using it and call the pharmacy and your prescriber. Check your lot number.

Two scientists in lab coats look closely at a small glass vial — Two scientists check a vial in a National Cancer Institute lab (2000 photo).Photo: Bill Branson, National Cancer Institute (NIH), public domain

1. What was recalled

FDA recall records list Apothecary Pharma LLC of Cary, North Carolina. The product is tirzepatide injection, 18 mg/mL, in 4 mL multi-dose vials. That is 22 vials, sent nationwide. Beyond-use dates run from October 7 to November 26, 2026.

The reason given is "lack of assurance of sterility." That means the maker could not show the shots were made in a way that keeps germs out. The same recall lists 1 vial of NAD+ injection (lot AP-202647). NAD+ is not a peptide.

2. Key dates

The company started the recall on September 24, 2026, by letter. FDA classified it as Class II on October 8, 2026, and listed it in the October 14 Enforcement Report. Some news stories gave other dates. We used the date in the FDA record. See the FDA record (event 99952).

FDA says a Class II recall is when a product may cause short-term or medically reversible health problems, or the chance of serious harm is remote.

3. A second recall the same day

FDA also classified a Class II recall from Carolina Infusion LLC of Ridgeland, South Carolina, on October 8. It covers pharmacy-made tirzepatide, semaglutide (some with vitamin B12), and sermorelin in syringes, also for lack of assurance of sterility. See the FDA record (event 99867).

Peptide and GLP-1 recalls we track

37 recall records from FDA reports, by drug, by reason, and by how serious

By drug

2184

Semaglutide 21
Tirzepatide 8
Glutathione 4
NAD+ 1
Sermorelin 1
Exenatide 1
Liraglutide 1

By reason

1614

No proof it was sterile 16
Bits floating inside 14
Germ toxins (endotoxin) 2
Germs found 2
Factory rules not followed 2
Pen might be empty 1

By how serious (FDA class)Class I is the most serious

Class II 33
Not classed yet 2
Class I 2

Most recalls were for compounded copies, mainly because no one could prove they were sterile.

Show the numbers as a table

Peptide and GLP-1 recalls we track
Grouped by	Breakdown	Total
By drug	Semaglutide: 21; Tirzepatide: 8; Glutathione: 4; NAD+: 1; Sermorelin: 1; Exenatide: 1; Liraglutide: 1	37
By reason	No proof it was sterile: 16; Bits floating inside: 14; Germ toxins (endotoxin): 2; Germs found: 2; Factory rules not followed: 2; Pen might be empty: 1	37
By how serious (FDA class)	Class II: 33; Not classed yet: 2; Class I: 2	37

One recall can have several records (one per product or strength). FDA Enforcement Report data last updated 2026-10-14; our list was checked 2026-10-21. Glutathione and NAD+ are not peptide drugs but are sold by the same shops. Sources: FDA Drug Enforcement Report (openFDA); Our recall checker (every record, with links).

4. What this does not mean

We found no 2026 recall of brand-name Zepbound or Mounjaro in FDA's Enforcement Report data. A recall covers only the listed lots. Compounded GLP-1 drugs are not FDA approved, and the FDA does not check them before they are sold.

5. What to do

Check the lot on your label with our recall checker.
If it matches, stop using it. Call the pharmacy and your prescriber.
If you feel sick, get medical help. Report problems to FDA MedWatch.

Check any peptide in 1 secondFree FDA Status Checker: approved, being tested, or not proven.

Companies are named only because the FDA names them in public recall records. Not medical advice. Medical disclaimer.